McNeil sales
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's McNeil division's fourth-quarter sales were flat, the firm reports in Jan. 24 fourth-quarter/year-end call. The shift of consumer products sold overseas such asPepcid and Imodium from the pharma division to McNeil offset a 4% drop in sales that was mainly due to state and retail restrictions on the sale of pseudoephedrine, J&J said. The firm reclassified the products in January 2005 (1"The Tan Sheet" July 25, 2005, p. 10). Full-year consumer segment sales grew 9% to $9 bil....